Effect of Resveratrol-Based Nutritional Supplement on Choroidal Thickness: A Pilot Study

Shuaishuai Wang, Nived Moonasar, Xiao Xiao, Tiemei Yin, Robert N. Weinreb, Xufang Sun

Research output: Contribution to journalArticle

  • 3 Citations

Abstract

Purpose: The effect of an oral trans-resveratrol-based supplement (Longevinex®) on choroidal thickness, measured using optical coherence tomography (OCT) enhanced depth imaging, was investigated in a prospective study. Materials and Methods: 34 young, healthy participants were randomly divided into two age- and gender-matched groups. They were then assigned in a randomized fashion to treat with either a trans-resveratrol-based group (Longevinex®, Las Vegas) or placebo. All participants underwent ocular imaging with spectral domain (SD)-OCT (Spectralis; Heidelberg Engineering, Heidelberg) at the baseline and then again 1 h following treatment. The choroidal thickness was measured in a masked fashion at the fovea and at four additional points, located at 500 μm and 1000 μm nasal to the fovea and 500 μm and 1000 μm temporal to the fovea. Results: In the resveratrol group, the foveal choroidal thickness at the baseline was 267.73 ± 84.19 μm (mean ± SD); it increased to 284.57 ± 92.39 μm 1 h after drug treatment (p = 0.033). The mean choroidal thickness was also significantly increased at each of the four extrafoveal points (all p <0.05). In the control group, the mean baseline choroidal thickness at the fovea was 269.73 ± 71.40 μm (mean ± SD) and it was 268.43 ± 70.15 μm (mean ± SD) 1 h after the placebo was administered (p = 0.183); there were also no significant differences in choroidal thickness at the four additional points (all p > 0.05) Conclusion: A significant increase in choroidal thickness following oral administration of a trans-resveratrol-based supplement was observed. There was no change in choroidal thickness in the placebo-treated control group. We speculate that the increased choroidal thickness is the result of choroidal vessel vasodilation.

LanguageEnglish (US)
Pages1-7
Number of pages7
JournalCurrent Eye Research
DOIs
StateAccepted/In press - Feb 11 2016
Externally publishedYes

Fingerprint

Placebos
Optical Coherence Tomography
Control Groups
Nose
Vasodilation
Oral Administration
Healthy Volunteers
Research Design
Prospective Studies
resveratrol
Therapeutics
Pharmaceutical Preparations

Keywords

  • Choroidal blood flow
  • choroidal thickness
  • enhanced depth imaging
  • optical coherence tomography
  • trans-resveratrol

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Effect of Resveratrol-Based Nutritional Supplement on Choroidal Thickness : A Pilot Study. / Wang, Shuaishuai; Moonasar, Nived; Xiao, Xiao; Yin, Tiemei; Weinreb, Robert N.; Sun, Xufang.

In: Current Eye Research, 11.02.2016, p. 1-7.

Research output: Contribution to journalArticle

Wang, Shuaishuai ; Moonasar, Nived ; Xiao, Xiao ; Yin, Tiemei ; Weinreb, Robert N. ; Sun, Xufang. / Effect of Resveratrol-Based Nutritional Supplement on Choroidal Thickness : A Pilot Study. In: Current Eye Research. 2016 ; pp. 1-7
@article{09358b4492e64456bc9ff487b0e41586,
title = "Effect of Resveratrol-Based Nutritional Supplement on Choroidal Thickness: A Pilot Study",
abstract = "Purpose: The effect of an oral trans-resveratrol-based supplement (Longevinex{\circledR}) on choroidal thickness, measured using optical coherence tomography (OCT) enhanced depth imaging, was investigated in a prospective study. Materials and Methods: 34 young, healthy participants were randomly divided into two age- and gender-matched groups. They were then assigned in a randomized fashion to treat with either a trans-resveratrol-based group (Longevinex{\circledR}, Las Vegas) or placebo. All participants underwent ocular imaging with spectral domain (SD)-OCT (Spectralis; Heidelberg Engineering, Heidelberg) at the baseline and then again 1 h following treatment. The choroidal thickness was measured in a masked fashion at the fovea and at four additional points, located at 500 μm and 1000 μm nasal to the fovea and 500 μm and 1000 μm temporal to the fovea. Results: In the resveratrol group, the foveal choroidal thickness at the baseline was 267.73 ± 84.19 μm (mean ± SD); it increased to 284.57 ± 92.39 μm 1 h after drug treatment (p = 0.033). The mean choroidal thickness was also significantly increased at each of the four extrafoveal points (all p <0.05). In the control group, the mean baseline choroidal thickness at the fovea was 269.73 ± 71.40 μm (mean ± SD) and it was 268.43 ± 70.15 μm (mean ± SD) 1 h after the placebo was administered (p = 0.183); there were also no significant differences in choroidal thickness at the four additional points (all p > 0.05) Conclusion: A significant increase in choroidal thickness following oral administration of a trans-resveratrol-based supplement was observed. There was no change in choroidal thickness in the placebo-treated control group. We speculate that the increased choroidal thickness is the result of choroidal vessel vasodilation.",
keywords = "Choroidal blood flow, choroidal thickness, enhanced depth imaging, optical coherence tomography, trans-resveratrol",
author = "Shuaishuai Wang and Nived Moonasar and Xiao Xiao and Tiemei Yin and Weinreb, {Robert N.} and Xufang Sun",
year = "2016",
month = "2",
day = "11",
doi = "10.3109/02713683.2015.1119282",
language = "English (US)",
pages = "1--7",
journal = "Current Eye Research",
issn = "0271-3683",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Effect of Resveratrol-Based Nutritional Supplement on Choroidal Thickness

T2 - Current Eye Research

AU - Wang,Shuaishuai

AU - Moonasar,Nived

AU - Xiao,Xiao

AU - Yin,Tiemei

AU - Weinreb,Robert N.

AU - Sun,Xufang

PY - 2016/2/11

Y1 - 2016/2/11

N2 - Purpose: The effect of an oral trans-resveratrol-based supplement (Longevinex®) on choroidal thickness, measured using optical coherence tomography (OCT) enhanced depth imaging, was investigated in a prospective study. Materials and Methods: 34 young, healthy participants were randomly divided into two age- and gender-matched groups. They were then assigned in a randomized fashion to treat with either a trans-resveratrol-based group (Longevinex®, Las Vegas) or placebo. All participants underwent ocular imaging with spectral domain (SD)-OCT (Spectralis; Heidelberg Engineering, Heidelberg) at the baseline and then again 1 h following treatment. The choroidal thickness was measured in a masked fashion at the fovea and at four additional points, located at 500 μm and 1000 μm nasal to the fovea and 500 μm and 1000 μm temporal to the fovea. Results: In the resveratrol group, the foveal choroidal thickness at the baseline was 267.73 ± 84.19 μm (mean ± SD); it increased to 284.57 ± 92.39 μm 1 h after drug treatment (p = 0.033). The mean choroidal thickness was also significantly increased at each of the four extrafoveal points (all p <0.05). In the control group, the mean baseline choroidal thickness at the fovea was 269.73 ± 71.40 μm (mean ± SD) and it was 268.43 ± 70.15 μm (mean ± SD) 1 h after the placebo was administered (p = 0.183); there were also no significant differences in choroidal thickness at the four additional points (all p > 0.05) Conclusion: A significant increase in choroidal thickness following oral administration of a trans-resveratrol-based supplement was observed. There was no change in choroidal thickness in the placebo-treated control group. We speculate that the increased choroidal thickness is the result of choroidal vessel vasodilation.

AB - Purpose: The effect of an oral trans-resveratrol-based supplement (Longevinex®) on choroidal thickness, measured using optical coherence tomography (OCT) enhanced depth imaging, was investigated in a prospective study. Materials and Methods: 34 young, healthy participants were randomly divided into two age- and gender-matched groups. They were then assigned in a randomized fashion to treat with either a trans-resveratrol-based group (Longevinex®, Las Vegas) or placebo. All participants underwent ocular imaging with spectral domain (SD)-OCT (Spectralis; Heidelberg Engineering, Heidelberg) at the baseline and then again 1 h following treatment. The choroidal thickness was measured in a masked fashion at the fovea and at four additional points, located at 500 μm and 1000 μm nasal to the fovea and 500 μm and 1000 μm temporal to the fovea. Results: In the resveratrol group, the foveal choroidal thickness at the baseline was 267.73 ± 84.19 μm (mean ± SD); it increased to 284.57 ± 92.39 μm 1 h after drug treatment (p = 0.033). The mean choroidal thickness was also significantly increased at each of the four extrafoveal points (all p <0.05). In the control group, the mean baseline choroidal thickness at the fovea was 269.73 ± 71.40 μm (mean ± SD) and it was 268.43 ± 70.15 μm (mean ± SD) 1 h after the placebo was administered (p = 0.183); there were also no significant differences in choroidal thickness at the four additional points (all p > 0.05) Conclusion: A significant increase in choroidal thickness following oral administration of a trans-resveratrol-based supplement was observed. There was no change in choroidal thickness in the placebo-treated control group. We speculate that the increased choroidal thickness is the result of choroidal vessel vasodilation.

KW - Choroidal blood flow

KW - choroidal thickness

KW - enhanced depth imaging

KW - optical coherence tomography

KW - trans-resveratrol

UR - http://www.scopus.com/inward/record.url?scp=84958548936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958548936&partnerID=8YFLogxK

U2 - 10.3109/02713683.2015.1119282

DO - 10.3109/02713683.2015.1119282

M3 - Article

SP - 1

EP - 7

JO - Current Eye Research

JF - Current Eye Research

SN - 0271-3683

ER -